Biotechnology · Healthcare
Janet Hammond
Equibles does not estimate personal net worth.
Get an email with a short summary when Atea Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AVIR alertsAbout Janet Hammond
The proxy statement of Atea Pharmaceuticals, Inc. reports total compensation of $1,767,234 for Janet Hammond in fiscal 2025, including a base salary of $590,892. Disclosed compensation is on record for 6 fiscal years. Janet Hammond has spoken on 4 earnings calls and 1 other investor event across 1 company, most recently for Atea Pharmaceuticals, Inc. on November 9, 2026. Atea Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Atea Pharmaceuticals, Inc. includes Jean-Pierre Sommadossi (CEO and Board Member), Andrea Corcoran (CFO), Wayne Foster (Chief Accounting Officer) and 7 others.
Janet Hammond on recent calls
“Bemrusesvir is a once-daily fixed-dose regimen. Benifospivir is a highly potent HCV nucleotide, and rusesvir is a highly The potent NS5A inhibitor. Together, they have been administered to thousands of individuals with generally favorable safety and tolerability.”
“From a regulatory perspective, as JT mentioned, we're aiming to file the NDA mid-next year, and we're already actively preparing for that regulatory submission with drafting documents, drafting the label, and discussing things with physicians.”
“Following EASL, ATAR held a hepatitis C key opinion leader event that featured a panel of six leaders in hepatology, gastroenterology, infectious disease, and HCV research from the U.S., Canada, and Europe.”
“Turning to slide 20, COVID-19 continues to evolve, and as Jean-Pierre mentioned earlier, we're now experiencing a summer wave across the US, Europe, and other global locations, which is largely being driven by the new KP and LB.1 variants.”
“To reiterate Jean-Pierre's earlier remarks, COVID-19 continues to be an established pathogen of concern with significant unmet need despite the availability of approved vaccines and antiviral treatment options.”
Affiliation history
-
Atea Pharmaceuticals, Inc. (AVIR)
Proxy statement
CurrentStart not stated–present
Last confirmed April 27, 2026
Company network
Leadership on record at Atea Pharmaceuticals, Inc.
- Jean-Pierre Sommadossi CEO, Board Member
- Andrea Corcoran CFO
- Wayne Foster Chief Accounting Officer
- Arthur Kirsch Board Member
- Barbara Duncan Board Member
- Bruce Polsky Board Member
- Bruno Lucidi Board Member
- Franklin Berger Board Member
- Howard Berman Board Member
- Howard H. Berman Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Atea Pharmaceuticals, Inc. (AVIR) | MD, PhD Chief Development Officer | $590,892 | $1,767,234 |
| 2024 | Atea Pharmaceuticals, Inc. (AVIR) | MD, PhD Chief Development Officer | $573,682 | $2,159,031 |
| 2023 | Atea Pharmaceuticals, Inc. (AVIR) | MD, PhD Chief Development Officer | $556,973 | $2,107,297 |
| 2022 | Atea Pharmaceuticals, Inc. (AVIR) | MD, PhD Chief Development Officer | $530,450 | $2,112,151 |
| 2021 | Atea Pharmaceuticals, Inc. (AVIR) | M.D., Ph.D. Chief Development Officer | $515,000 | $9,007,023 |
| 2020 | Atea Pharmaceuticals, Inc. (AVIR) | M.D., Ph.D. Chief Development Officer | $197,115 | $4,030,318 |